MT Pharmacy

Eltrombopag 50 mg Tablet is prescribed to raise platelet counts in patients with chronic immune thrombocytopenia, hepatitis C–associated thrombocytopenia, and severe aplastic anemia. It works by stimulating platelet production in the bone marrow, reducing bleeding risks. Regular monitoring is essential to ensure safe, effective treatment and proper dose adjustment.

Rebopag 25 mg Tablets contain Eltrombopag, a thrombopoietin receptor agonist used to increase platelet counts in patients with chronic immune thrombocytopenia, hepatitis C–related thrombocytopenia, and severe aplastic anemia. It boosts platelet production in the bone marrow. Treatment must be supervised by a physician, with regular monitoring for safe and effective therapy.

Revolade 50 mg Tablets contain Eltrombopag, a thrombopoietin receptor agonist used to increase platelet counts in patients with chronic immune thrombocytopenia, hepatitis C–related thrombocytopenia, and severe aplastic anemia. It boosts platelet production in the bone marrow, reducing bleeding risks. Treatment requires medical supervision and regular monitoring for safe, effective results.

Elromo 50 mg Tablets contain Eltrombopag, a thrombopoietin receptor agonist used to increase platelet counts in patients with chronic immune thrombocytopenia, hepatitis C–related thrombocytopenia, and severe aplastic anemia. It stimulates platelet production in the bone marrow. Treatment requires strict medical supervision, regular monitoring, and dose adjustments to ensure safe, effective therapy.

Eltropag 50 mg Tablet contains Eltrombopag, used to increase platelet production in patients with chronic immune thrombocytopenia, hepatitis C–associated thrombocytopenia, and severe aplastic anemia. It stimulates the bone marrow to raise platelet counts and reduce bleeding risk. Treatment requires strict medical supervision and regular blood monitoring for safe, effective use.

Eltropag 25 mg Tablets contain Eltrombopag, a thrombopoietin receptor agonist used to increase platelet counts in patients with chronic immune thrombocytopenia, hepatitis C–related thrombocytopenia, and severe aplastic anemia. It boosts platelet production in the bone marrow. Treatment requires medical supervision, dose adjustments, and regular blood monitoring for safe, effective results.

Trombonat 50 mg Tablets contain Eltrombopag, a thrombopoietin receptor agonist used to increase platelet counts in patients with chronic immune thrombocytopenia, hepatitis C–related thrombocytopenia, and severe aplastic anemia. It stimulates platelet production in the bone marrow. Treatment requires strict medical supervision, regular blood tests, and dose adjustments to ensure safe, effective therapy.

Platepag MI 50 mg Tablets contain Eltrombopag, a platelet-stimulating medicine used to treat chronic immune thrombocytopenia, hepatitis C–related low platelets, and severe aplastic anemia. It increases platelet production in the bone marrow, helping reduce bleeding risks. Treatment requires strict medical supervision, regular blood monitoring, and careful dose adjustments for safe, effective use.

Revugam 50 mg Tablets contain Eltrombopag, a thrombopoietin receptor agonist used to increase platelet counts in patients with chronic immune thrombocytopenia, hepatitis C–related thrombocytopenia, and severe aplastic anemia. It works by stimulating platelet production in the bone marrow. Treatment requires close medical supervision, dose adjustments, and regular blood monitoring for safety.

Revolade 25 mg Tablet contains Eltrombopag, a medicine used to increase platelet counts in patients with chronic immune thrombocytopenia, hepatitis C–related thrombocytopenia, and severe aplastic anemia. It stimulates platelet production in the bone marrow, reducing bleeding risks. Treatment requires medical supervision, dose adjustment, and regular blood monitoring for safety and effectiveness.

Trombonat 25 mg Tablets contain Eltrombopag, a platelet-boosting medicine used to treat chronic immune thrombocytopenia, hepatitis C–related thrombocytopenia, and severe aplastic anemia. It works by stimulating platelet production in the bone marrow, helping reduce bleeding risks. Therapy requires strict medical supervision, regular blood tests, and appropriate dose adjustment for safety and effectiveness.

Platify 50 mg Tablets are formulated to help manage pain and inflammation by reducing swelling and discomfort at the source. These tablets provide effective relief with consistent therapeutic action, supporting faster recovery and improved daily comfort. They should be taken as directed by a healthcare professional for safe and optimal results.

Eltrombopag Olamine 25 mg Tablets are used to increase platelet production in patients with chronic immune thrombocytopenia, hepatitis C–related thrombocytopenia, and severe aplastic anemia. By stimulating bone marrow activity, they help reduce bleeding risks. The medicine requires strict medical supervision, dosage control, and regular monitoring for safe, effective treatment.

Eltrombopag 25 mg Tablets are used to increase platelet counts in patients with chronic immune thrombocytopenia, hepatitis C–related thrombocytopenia, and severe aplastic anemia. The medicine stimulates platelet production in the bone marrow, helping reduce bleeding risk. It should be taken exactly as prescribed, with regular monitoring for safe and effective treatment.

Platify 25 mg Tablets contain Eltrombopag Olamine, used to increase platelet counts in patients with chronic immune thrombocytopenia, hepatitis C–related thrombocytopenia, and severe aplastic anemia. The medicine enhances platelet production in the bone marrow, helping lower bleeding risks. Regular monitoring and medical guidance are essential for safe, effective use.

Eltrombopag 25 mg Tablets are used to increase platelet counts in patients with chronic immune thrombocytopenia, hepatitis C–related thrombocytopenia, and severe aplastic anemia. The medicine stimulates platelet production in the bone marrow, helping reduce bleeding risk. It should be taken exactly as prescribed, with regular monitoring for safe and effective treatment.